A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab

PHASE2TerminatedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

December 3, 2012

Primary Completion Date

December 24, 2024

Study Completion Date

December 24, 2024

Conditions
Glioma
Interventions
DRUG

Bevacizumab

10mg/kg every 2weeks.

RADIATION

PRDR

Daily dose of 2.0gy delivered in .2gy pulses for a total of 54gy over 5.5 weeks and 27 fractions. In the rare instance of the presence of extensive disease requiring essentially whole brain radiation, a total daily dose of 1.8 Gy delivered in .2 Gy pulses for 23 fractions to a total dose of 41.4 Gy will be utilized.

Trial Locations (1)

53792

University of Wisconsin Hospital and Clinics, Madison

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

University of Wisconsin, Madison

OTHER